Belfast, UK. 4th January, 2021.

CV6 Therapeutics, a drug development company focussed on the development and commercialisation of novel combination therapeutics for cancer and inflammatory diseases, today announced that they have been recognised as a Platinum Level Innovator by Innovate Northern Ireland on behalf of the Department of the Economy for Northern Ireland.

The award was based on CV6’s ability to consistently demonstrate innovation by creating value and opportunity from its ideas and business model.

“We are both delighted and humbled that CV6 has been awarded Platinum Innovator status by the Department of the Economy for NI” said CV6 CEO Robert Ladner. “Despite the fact that 2020 was a challenging year for many NI businesses while navigating the ongoing pandemic, CV6 continues to advance its objective to deliver a first-in-human clinical trial for CV6-168, our lead oncology therapeutic. Receiving this award saw 2020 end on a high note. I would like to thank all CV6 staff for their continued hard work and our partners, including Queen’s University Belfast and Invest Northern Ireland, for their continued dedication to help CV6 achieve its goals.”

CV6-168 is the most advanced therapeutic in CV6’s innovative pipeline and represents an exciting opportunity to significantly improve treatment outcomes for patients across multiple cancer indications, including some of the most difficult-to-treat cancers that currently lack effective therapies.

Innovate NI delivers the Innovation Accreditation Programme which aims to increase the number of local businesses innovating successfully.

More information on Innovate NI and how to successfully innovate in your business can be found on their website: https://www.innovateni.com/use-innovation-grow-your-business

CV6 Therapeutics

CV6 Therapeutics is a drug development company focused on the discovery, development and commercialization of novel therapies for the treatment of human diseases. To learn more about CV6 Therapeutics and its product pipeline including CV6-168, or to contact us, click here:  CV6 Therapeutics